These data support the idea that MERTK-L593G is an inhibitor-resistant but catalytically active MERTK mutant and demonstrate signaling through AKT-S6 downstream of MERTK in 633 NSCLC cells. The gene discussed is AKT1; the disease is non-small cell lung carcinoma.